All News

JIA_0.jpg

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA

Jack Cush, MD

JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.

Read Article
Screen%20Shot%202020-03-27%20at%2010.15.17%20AM.png

Global Mortality Rates for PsA, SpA and Colitis

Jack Cush, MD

Global age-standardized mortality rate (ASMR) for 1000000 was for 0.13 for AS, 0.04 for PsA, 0.86 for CD and 0.76 for UC.

Read Article
RheumNow Podcast square

Hit Parade Review (8.12.2022)

Jack Cush, MD

We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more. In what order should these items be discussed? This week the run down is based on popularity, measured by rheumatologist engagements on the website and social media.

Read Article
morbidity,covid,heart,lung,brain

Arthritis - a Leading Chronic Condition Among Young Adults (18─34 Yrs)

Jack Cush, MD

MMWR from last week focused on chronic conditions in young adults showing they are common, costly, and major causes of death and disability. Overall arthritis ranks behind five more common chronic condition in young adults - obesity, depression, hypertension, hypercholesterolemia and asthma.

Read Article
Sleep.fatigue.doctor.jpg

Fatigue is Under-Appreciated in Psoriatic Arthritis

Jack Cush, MD

Patient-reported fatigue is high in patients with psoriatic arthritis (PsA) and often goes under-recognized by physicians. Fatigue importantly impacts physical functioning, work productivity, and health related quality of life (HRQoL).

Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.

Read Article
ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Jack Cush, MD

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Read Article
Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!

Dr. John Cush RheumNow ( View Tweet)

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study https://t.co/1fiNgBQUbr looks like lower ab response and drops over 6 mths - boosters important in our patients

Links:

Peter Nash drpnash ( View Tweet)

Global Mortality Rates for PsA, SpA and Colitis Global age-standardized mortality rate (ASMR) for 1000000 was for 0.13 for AS, 0.04 for PsA, 0.86 for CD and 0.76 for UC. https://t.co/0cZ9kZsiEM https://t.co/hDHojKBeRQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Lilly has announced that Taltz (ixekizumab) is now available as a Citrate-Free Formulation to reduce injection site pain for patients with psoriasis, psoriatic arthritis, spondyloarthritis & nonradiographic axial spondyloarthritis. https://t.co/mTBl9siLED https://t.co/TCFqdK58dA

Links:

Dr. John Cush RheumNow ( View Tweet)
Fatigue is Under-Appreciated in Psoriatic Arthritis Patient-reported fatigue is high in patients with psoriatic arthritis (PsA) and often goes under-recognized by physicians. https://t.co/mb80NHH0dr https://t.co/an4rq1BPut

Links:

Dr. John Cush RheumNow ( View Tweet)
150 PsA pts assessed preferences in chosing biologics (of most to less preferred): 1 Oral over SC or IV routes 2 Avoiding severe side effects 3 Resume normal activity 4 Avoid infections 5 Improve enthesitis & 6 psoriasis 7 remission 8 Joint pain https://t.co/kE3qtTWBhH https://t.co/KKcsQqEYKf

Links:

Dr. John Cush RheumNow ( View Tweet)
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/7bGJ0ZCJJl https://t.co/GtuXdHj3Og

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA Females: more likely to have Peripheral arthritis, have more pain, fatigue, poor function, lower QOL and less likely to have xray damage (than men) Males: more axial dz & severe psoriasis PsA Women may need more psychosocial support & pain management https://t.co/ZYWYu1K3jW https://t.co/xZX913vGdX

Links:

Dr. John Cush RheumNow ( View Tweet)
New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." https://t.co/PkDofio1eh https://t.co/kp6UEgwonV

Links:

Dr. John Cush RheumNow ( View Tweet)
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/qDuCgUwmZV https://t.co/c0a7723A1X https://t.co/v5T66iKnvc

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center, retrospective chart study shows that in 168 PsA patients, 26% were assessed within 6wks of referral. Median wait time = 78.5 d. The most common cause of delay was the lack of available spots in the PsA clinic. https://t.co/FDfFgxHhLD https://t.co/CYoT1PBp8l

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×